
Potential participants responding to advertisements (n=514)
Not invited to screening (n=234)
Not meeting inclusion criteria (n=72)
Did not wish to participate (n=162)
Invited to screening/consent session (n=280)
Attended screening/consent session (n=144)
Not eligible (n=10)
Medical reasons (n=6)
No GP (n=1)
Cannot attend sessions (n=2)
Does not want to use varenicline (n=1)
Randomised (n=117)
Did not attend randomisation session (n=17)
Allocation
Allocated to placebo patch (n=59)
Allocated to nicotine patch (n=58)
Follow-up
Completed follow up at 12- weeks post TQD (n=31)
Completed follow up at 12-weeks post TQD (n=33)
Analysis
For abstinence evaluation, those lost to follow-up (n=28) were included as non-abstainers
For abstinence evaluation, those lost to follow-up (n=25) were included as non-abstainers